Partnering
MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.
Learn moreCompany Highlights
- Robust pipeline in oncology, autoimmunity and infectious diseases
- Partners include Boehringer Ingelheim, Gilead, Pfizer and Servier
- Fully-integrated biologics capabilities across product development process
- Strong financial position and blue-chip investor base
- Experienced management team and highly collaborative corporate culture
Overview
Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.
Learn moreIn the News
2011 News Archive
December 23, 2011 | Gazette.Net
MacroGenics, BrainScope Among Bioscience Winners
December 01, 2011 | Fierce Biotech
MacroGenics Pockets $20M in $450 Deal with Servier
December 01, 2011 | Bio World
MacroGenics 'Serves' Early Stage Antibody Deal: Potential $450M
December 01, 2011 | Washington Business Journal
MacroGenics Inks Pharma Deal Worth up to $450 Million
November 30, 2011 | "The Pink Sheet" Daily
Servier, MacroGenics Forge Option Deal for Cancer Drug
July 14, 2011 | Medpage Today
ADA: Drug Misses Type 1 Goal, but May Help Beta Cells
June 07, 2011 | Wall Street Journal
Trying to Prevent Type 1 Diabetes
June 07, 2011
Why Diabetes Prevention Might Work When Treatment Doesn't
April 28, 2011 | Inside Blood
DARTs Take Aim at BiTEs
January 18, 2011 | Nature Biotechnology
Boehringer Splashes out on Bispecific Antibody Platforms
News Archive: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All